TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02536833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03612895

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
Study: NCT00738517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immunoadsorption / Immunoglobulin substitution
Description: Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
Study: NCT03954938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
Study: NCT01800149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge Augmentation
Description: After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge Augmentation
Description: After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
Study: NCT03949751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne Crème Plus
Description: The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Study: NCT00059254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleic acid (OA)
Description: OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitic Acid (PA)
Description: PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
Study: NCT01306708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
Study: NCT03682822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Artificial rupture of membranes
Description: Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Artificial rupture of membranes
Description: Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
Study: NCT02938741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human Thymoglobulin
Description: r-ATG 2.5MG/KG\*4days were used in the conditioning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: r-ATG 2.5MG/KG\*4days were not used in the conditioning
Study: NCT04592614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move - Next Steps
Description: Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move - Next Steps
Description: Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
Study: NCT00535912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells autograft
Description: Treatment by Intensive Chemotherapy and autograft
Study: NCT01795066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Study: NCT02741180

Intervention type: OTHER
Group type: OTHER
Intervention: 3D Imaging
Description: roadmapping of electrophysiology (EP) procedures

Intervention type: OTHER
Group type: OTHER
Intervention: 3D Imaging
Description: roadmapping of electrophysiology (EP) procedures

Intervention type: OTHER
Group type: OTHER
Intervention: Late Gadolinium Enhancement (LGE)
Description: useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.

Intervention type: OTHER
Group type: OTHER
Intervention: Late Gadolinium Enhancement (LGE)
Description: useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
Study: NCT02220998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00945854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain cereal diet
Description: Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined cereal diet
Description: Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
Study: NCT04188171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Description: * Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months.
Study: NCT04231591

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP
Description: Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP
Description: Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
Study: NCT00321893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled Budesonide 800 micrograms (ug) twice daily for one year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo twice daily for one year.
Study: NCT04038632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decentralization of Childhood TB Diagnosis
Description: The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decentralization of Childhood TB Diagnosis
Description: The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
Study: NCT04204785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise Reduction Education
Description: OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
Study: NCT02874768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
Study: NCT01281527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: 50 - 150 mg eq. every 30 days
Study: NCT03783247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca BLock
Description: In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
Study: NCT01211587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
Study: NCT01251471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg/d; optional 20 mg/d after 2 weeks.
Study: NCT02526329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor regulatory T lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01627171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 10mg
Description: Given at the start of the bowel preparation the day before colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10mg
Description: Given at the start of the bowel preparation the day before colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10mg
Description: Given at the start of the bowel preparation the day before colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethelene Glycol
Description: 280g reconstituted in 4 liters of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosulfate sodium
Description: Two sachets, Each sachet has 10mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosulfate sodium
Description: Two sachets, Each sachet has 10mg dose
Study: NCT01357200

Intervention type: OTHER
Intervention: enteral formula
Description: Complete feeding of study enteral formula, route and regime prescribed by the physician.
Study: NCT04692740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil, Oral, 2 Mg
Description: Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
Study: NCT03227341

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
Study: NCT04109898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (I-gel) insertion
Description: Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
Study: NCT04330820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3.
Study: NCT04421807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapulatoracic stabilization exercises
Description: Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy (CDT)
Description: In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive therapy (CDT)
Description: In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
Study: NCT01958112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 (trametinib)
Description: Trametinib dose is 1.5 mg orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: The dose of GSK2141795 is 50 mg orally once per day
Study: NCT01085500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery Learning TEP Curriculum
Description: A simulation-based educational curriculum

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Current Practice
Description: The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
Study: NCT01513369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (0,9%)
Description: Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
Study: NCT03052933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
Study: NCT00730262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-4601
Description: 14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
Study: NCT00230477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepsera

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepsera and lamivudine
Study: NCT01326559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, 5-FU and Cetuximab
Description: Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)
Study: NCT02096575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous oxide administration
Description: All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB.